Related by context. All words. (Click for frequent words.) 71 HCV genotype 1 68 antiretroviral naive 67 treatment naive genotype 67 HCV infection 67 HIV uninfected 67 hepatitis C genotype 67 seronegative 67 metastatic RCC 67 chronic HCV infection 66 heavily pretreated 66 CCR5 tropic HIV 66 treatment naïve genotype 66 HCV 66 peginterferon 66 null responder 66 LTBI 66 null responder HCV 66 symptomatic BPH 65 HCV SPRINT 65 HBeAg positive 65 coinfected 65 virological response 65 T2DM 65 NNRTI resistance 65 APTIVUS r 65 chronic HCV 65 antiretroviral naïve 64 relapsed MM 64 immunocompetent 64 HIV HCV coinfected 64 imatinib therapy 64 HCV genotypes 64 CMV disease 64 chronically infected 64 HCV genotype 64 sustained virologic response 64 evaluable subjects 64 refractory CLL 64 lamivudine refractory patients 64 sustained virological response 63 cART 63 lamivudine 63 advanced NSCLC 63 HBeAg negative 63 KRAS mutations occur 63 virologic failure 63 complete cytogenetic response 63 ribavirin RBV 63 viremic 63 stage IIIB 63 tipranavir ritonavir 63 antiviral therapy 63 HAART 63 nitazoxanide 63 HCV infections 63 T1DM 63 EGFR mutations 63 RRMS patients 62 ritonavir boosted 62 follicular lymphomas 62 NNRTI 62 castration resistant prostate cancer 62 HSCT 62 HIV coinfected 62 dose escalation phase 62 leukemia AML 62 APTIVUS 62 LEXIVA r 62 INCB# [001] 62 decitabine 62 recurrent glioblastoma multiforme 62 chronic GVHD 62 NRTI resistance 62 lupus nephritis 62 antiangiogenic therapy 62 HBeAg negative chronic hepatitis 62 antiretroviral therapy 62 achieved sustained virological 62 pancreatic adenocarcinoma 62 virologic 62 liver transplant recipients 62 latent TB infection 62 Gleevec resistant 62 chronic hepatitis C 62 prostate carcinoma 62 pomalidomide 62 PegIFN RBV 62 virological failure 62 genotypic resistance 62 Gag polymorphisms 62 darunavir ritonavir 62 oral FTY# 62 relapsed AML 62 castrate resistant prostate cancer 62 hepatitis C HCV 61 HIV seronegative 61 VFEND 61 chronic HBV infection 61 adalimumab 61 recurrent glioma 61 T#I mutation 61 bendamustine 61 undetectable HBV DNA 61 lamivudine resistant 61 raltegravir 61 CR nPR 61 acute myelogenous leukemia AML 61 HBeAg seroconversion 61 highly immunogenic 61 autologous transplants 61 recurrent GBM 61 dosing cohort 61 K ras mutations 61 BCG vaccinated 61 pegylated interferon 61 CCR5 antagonist 61 protease inhibitor PI 61 peginterferon alfa 2a 61 metastatic malignant melanoma 61 posaconazole 61 genotype 1a 61 PRTX 61 mCRC patients 61 metastatic renal cell carcinoma 61 HBeAg positive patients 61 seroconverted 61 dosing cohorts 61 M#V mutation 61 HBV DNA 61 TMC# r 61 elacytarabine 61 HBV infection 61 refractory AML 61 colorectal liver metastases 61 mRCC 61 seropositive patients 61 imatinib 61 biochemical relapse 61 relapsing MS 61 unresectable stage 61 leukemia ALL 61 TMC# C# 61 chronic HCV genotype 61 leukemia CLL 61 HBsAg 61 dose cohort 61 evaluable patients 61 genotype 61 BARACLUDE ® 60 DAPT 60 cirrhotic 60 micafungin 60 octreotide LAR 60 pegylated interferon alpha 60 SCIg 60 achieved ACR# 60 adult chronic ITP 60 receiving antiretroviral therapy 60 viral kinetics 60 mCRPC 60 riociguat 60 Amigal 60 PREZISTA ritonavir 60 tuberculin skin testing 60 cytogenetic responses 60 seropositive 60 PREZISTA r 60 HBeAg 60 aged ≥ 60 HIV infected 60 BRAF V#E mutation 60 prostate cancer CRPC 60 dosage regimens 60 PD LID 60 histologically confirmed 60 COPAXONE R 60 forodesine 60 viremia 60 prostate cancer CaP 60 HBV 60 genotype 1b 60 eosinophilic asthma 60 nondiabetic 60 chemoradiotherapy 60 trastuzumab Herceptin ® 60 evaluable 60 CIMZIA ™ 60 YONDELIS 60 nucleotide analog 60 seropositivity 60 HCV RNA 60 GHRH 60 rindopepimut 60 relapsed ALL 60 diabetes mellitus DM 60 mg/m2 dose 60 mutated K ras 60 CIMZIA TM 60 mg kg dose 60 entecavir 60 disease progression 60 visilizumab 60 BRAF mutation 60 metastatic neuroendocrine tumors 60 Traficet EN 60 S. aureus infections 60 basal cell nevus syndrome 60 BCR ABL inhibitor 60 lymphocytosis 60 patients evaluable 60 underwent resection 60 Pegasys plus Copegus 60 chronic HBV 60 receiving immunosuppressive therapy 60 undetectable viral load 60 CC genotype 60 mcg dose 60 HAART regimens 60 infliximab 60 complete remissions 60 GH deficiency 60 BRAF V# mutation 60 pegylated interferon alfa 2a 60 FLT3 mutations 60 sunitinib 60 chlorambucil 60 rituximab refractory 60 pharmacokinetic interactions 60 CRp 60 chlamydial infection 60 potent antiretroviral therapy 60 relapsing remitting multiple sclerosis 60 Chronic Hepatitis C 59 Naive Patients 59 certolizumab 59 CCR5 tropic 59 viral load 59 NRTIs 59 anti TNF 59 clinical pharmacology studies 59 IFN beta 59 HIV RNA 59 complete cytogenetic 59 adrenalectomy 59 viral suppression 59 p# biomarker 59 enfuvirtide 59 osteosarcomas 59 NSCLC 59 dasatinib Sprycel 59 Ozarelix 59 chronic myeloid leukemia CML 59 lenalidomide Revlimid R 59 resected pancreatic cancer 59 genotyped 59 rituximab 59 HBeAg negative patients 59 Vacc 4x 59 splenectomized patients 59 virologic response 59 PsA 59 paroxysmal AF 59 Elitek 59 NNRTI resistant virus 59 selective modulator 59 dose cohorts 59 virologically 59 darunavir r 59 relapsed refractory multiple myeloma 59 nucleoside naive 59 AML MDS 59 CMV infection 59 Pharmacokinetics PK 59 liver histology 59 pegylated liposomal doxorubicin 59 immunosuppression 59 CLL SLL 59 superinfection 59 HCV RESPOND 2 59 genotypic 59 OncoVEX GM CSF 59 experienced virologic failure 59 prospectively defined 59 ascending doses 59 virus HCV infection 59 omega interferon 59 PROCHYMAL 59 peg interferon 59 CR# vcMMAE 59 HER2 positive metastatic breast 59 de novo AML 59 rhGH 59 preoperative chemotherapy 59 heavily pretreated patients 59 trabectedin 59 PROSTVAC VF 59 noninfectious uveitis 59 latent tuberculosis infection 59 miglustat 59 relapsing remitting MS RRMS 59 poor metabolizers 59 refractory NSCLC 59 relapsed ovarian cancer 59 CANCIDAS 59 AEG# 59 advanced neoplasia 59 immunomodulatory therapy 59 histologically proven 59 hepatitis C virus 59 HCV replicon 59 distant metastases 59 achieve sustained virologic 59 corticosteroid dose 59 latently infected 59 biologic therapy 59 CTAP# Capsules 59 chronic ITP patients 59 relapsed multiple myeloma 59 operable breast cancer 59 anagrelide 59 achieved CCyR 59 ceftazidime 59 ibandronate 59 adefovir 59 DLBCL 59 chronic hepatitis C. 59 pyridostigmine 59 evaluating tivozanib 59 receptor tyrosine kinase inhibitor 59 PREZISTA rtv 59 abnormal cytology 59 biliary tract cancer 59 KRAS mutations 59 tarenflurbil 59 transgenic rats 59 nab paclitaxel 59 Waldenstrom macroglobulinemia 58 undetectable HCV RNA 58 natalizumab 58 KRAS mutation 58 NLX P# 58 hepatocellular carcinoma HCC 58 carcinoid tumors 58 weekly subcutaneous injections 58 visceral metastases 58 glioblastoma tumors 58 metastatic prostate cancer 58 diabetic neuropathic pain 58 pancreatic neuroendocrine tumors 58 Phase 2a trial 58 Doxil ® 58 EGFR TKI 58 Aptivus ® 58 renal transplantation 58 hypogonadal men 58 atazanavir ritonavir 58 log# reduction 58 lymphoid malignancies 58 galiximab 58 prior chemotherapy regimens 58 sUA 58 HIV seropositive 58 TDF FTC 58 metastatic hormone refractory 58 transplantation HSCT 58 Reverset 58 lung metastases 58 systemic lupus erythematosus SLE 58 Blinatumomab 58 ADHF 58 Peg IFN 58 tipranavir 58 NRTI 58 neoadjuvant chemotherapy 58 dose escalation study 58 insulin degludec 58 virologic responses 58 phase IIb study 58 adjuvant tamoxifen 58 undetectable viral loads 58 mildly symptomatic 58 superficial bladder cancer 58 PCa 58 NNRTIs 58 HER2 positive cancers 58 HNSCC 58 administered subcutaneously 58 Asymptomatic 58 allogeneic stem cell 58 TACI Ig 58 octreotide 58 metastatic renal cell 58 bladder carcinoma 58 pegylated interferon alfa 2b 58 pCR 58 Virulizin ® 58 tamoxifen therapy 58 azacitidine 58 ABSSSI 58 recurrent malignant glioma 58 coinfected patients 58 IFN α 58 AGILECT R 58 clinically evaluable 58 Tipranavir 58 CHOP chemotherapy 58 abacavir Ziagen 58 seroconversion 58 acute ischemic stroke 58 ChronVac C ® 58 APTIVUS ritonavir 58 androgen independent 58 Phase 1b 58 allogeneic SCT 58 metastatic disease 58 naïve HCV 58 ascending dose 58 metastatic lung cancer 58 papillary renal cell carcinoma 58 hepatocellular cancer 58 Myelodysplastic Syndrome MDS 58 mutated KRAS 58 renal tumors 58 Bezielle 58 H pylori 58 relapsed SCLC 58 Flu Cy 58 paclitaxel eluting stents 58 Phase 2b study 58 isolated systolic hypertension 58 RESIST studies 58 inhibitor RG# 58 ESRD patients 58 rHuPH# 58 Atypical Hemolytic Uremic Syndrome 58 myeloablative 58 receiving VICTRELIS 58 imatinib Gleevec 58 chronic ITP 58 HBV vaccine 58 resistant isolates 58 tocilizumab 58 HBeAg + 58 Chronic Myeloid Leukemia 58 castrate resistant 58 liver biopsies 58 cisplatin chemotherapy 58 phase IIa clinical 58 medullary thyroid cancer 58 receptor inhibitor 58 ano genital warts 58 de novo kidney transplant 58 phase IIb clinical 58 Genasense ® 58 Nilotinib 58 methotrexate therapy 58 tgAAC# 58 adjuvant therapy 58 AZT zidovudine Retrovir 58 GIST tumors 58 MPS IVA 58 pDCs 58 maximally tolerated dose 58 sunitinib malate 58 adalimumab Humira 58 relapsed refractory AML 58 interferon alfa 58 euthyroid 58 active comparator 58 anti leukemic 58 undergone radical prostatectomy 58 hormone deprivation 58 HGS ETR1 58 immunosuppressive regimens 58 recurrent glioblastoma 58 hepatorenal syndrome 58 rapid virologic response 58 T#I [002] 58 caspofungin 58 vWD 58 MGd 58 n = 58 goserelin 58 N. gonorrhoeae 58 nucleoside analogues 58 intravenous bisphosphonates 58 malignant pleural mesothelioma 58 interferon ribavirin 58 viral loads 58 dose escalation clinical 58 Hepatocellular Carcinoma HCC 58 gefitinib 58 glucose intolerant 58 BCG refractory 58 flutamide 58 cystectomy 58 Raptiva r 58 allogeneic transplant 58 latent TB 58 KRAS wild 58 ORENCIA ® 58 pegylated interferon alfa 58 LHRH receptor positive 58 docetaxel chemotherapy 58 mycophenolate mofetil 58 erlotinib Tarceva ® 57 C1 INH 57 advanced adenomas 57 HBV infections 57 bevirimat 57 decompensated liver disease 57 linezolid 57 serum HCV RNA 57 dose dose escalation 57 Dr. McHutchison 57 darunavir 57 hepatic fibrosis 57 Enzastaurin 57 antibody MAb 57 stage IIIb IV 57 vicriviroc 57 cognitively normal 57 asymptomatic 57 solifenacin 57 nelfinavir 57 Cethromycin 57 HPTN 57 methotrexate monotherapy 57 LUX Lung 57 NMIBC 57 chronic lymphocytic leukemia CLL 57 CDAD 57 untreated AML 57 posttransplant 57 mcg albinterferon alfa 2b 57 virologic suppression 57 CYP#C# * 57 virological 57 radezolid 57 Median survival 57 Infected Patients 57 DEB# 57 8mg/kg 57 IDX# 57 lymphocyte counts 57 nonalcoholic steatohepatitis NASH 57 trabedersen 57 underwent liver transplantation 57 remission induction 57 liver metastases 57 taxane resistant 57 ACTEMRA TM 57 Pegasys ® 57 locoregional 57 seliciclib 57 renal cell carcinomas 57 Phenoptin 57 HLA DR2 57 phase IIa 57 HoFH 57 oral rivaroxaban 57 Phase Ib II 57 teriflunomide 57 GBM tumors 57 tipranavir r 57 polymerase inhibitor 57 JAK inhibitors 57 oblimersen 57 HBV infected 57 ABCB1 57 R#/MEM # 57 RSD# oral 57 naive HCV 57 relapsed refractory 57 HAART regimen 57 fistulizing Crohn disease 57 systemic ALCL 57 genital HSV 57 metastatic castration resistant 57 CIMZIA TM certolizumab pegol 57 candidemia 57 CALGB # [002] 57 metastatic malignant 57 Dasatinib 57 elvucitabine 57 Omacetaxine 57 plus methotrexate 57 nucleoside analogue 57 ceftriaxone 57 HER2 positive breast cancer 57 alfa 2a 57 interferon beta therapy 57 insulin detemir 57 ALISTA 57 doripenem 57 recurrent NSCLC 57 hyperphenylalaninemia HPA due 57 gastrointestinal stromal tumors 57 CYPHER Stent 57 FOLFOX4 57 piperacillin tazobactam 57 canakinumab 57 lipid lowering therapy 57 gefitinib Iressa 57 anemia hemoglobin 57 abacavir lamivudine 57 remission CR 57 antitumor effect 57 combination antiretroviral therapy 57 Virologic 57 autoantibody positive 57 VP# [004] 57 hepatocellular carcinoma 57 TG MV 57 serologic 57 alteplase 57 Pegylated Interferon 57 HeFH 57 allogeneic hematopoietic stem cell 57 peripheral blood mononuclear 57 BRIM3 57 budesonide foam 57 rilpivirine 57 #mg QD [002] 57 ovarian carcinoma 57 mg QD 57 placebo controlled clinical 57 pegylated alpha interferon 57 cabazitaxel 57 monoinfected patients 57 pyrazinamide 57 panobinostat 57 Prostate Lung Colorectal 57 KRAS status 57 mg ustekinumab 57 pentoxifylline 57 CYT# potent vascular disrupting 57 monotherapy 57 pheochromocytoma 57 novel VDA molecule 57 double blinded randomized 57 transcriptase inhibitor NNRTI 57 MELD scores 57 peg IFN 57 systemically administered 57 dose escalation 57 allogeneic bone marrow 57 APTIVUS R 57 thrombocytopenic 57 androgen deprivation 57 4CMenB 57 EBV infection 57 erlotinib 57 favorable pharmacokinetic profile 57 prostate cancer HRPC 57 pertuzumab 57 huN# DM1 57 BRAF V#E 57 rFVIIa 57 BENICAR HCT 57 relapsing multiple sclerosis 57 SHPT 57 colorectal carcinoma 57 abatacept 57 Peginterferon 57 taxane therapy 57 GnRH agonists 57 prostate adenocarcinoma 57 NAbs 57 low dose cytarabine 57 HBV DNA levels 57 cinacalcet 57 GOUT 57 mycophenolate mofetil MMF 57 ErbB2 positive 57 chemoradiation 57 β blockers 57 Phase Ib study 57 Velcade bortezomib 57 normotensive 57 Phase Ib clinical 57 subcutaneously administered 57 HGPIN 57 Natalizumab 57 antiretroviral therapy ART 57 undergoing radical prostatectomy 57 antiviral activity 57 alemtuzumab treated 57 plus dexamethasone 57 immunomodulator 57 PSADT 57 plus ribavirin 57 dasatinib Sprycel ® 57 glufosfamide 57 haematologic malignancies 57 Phase IIIb clinical 57 postexposure prophylaxis 57 mucosal healing 57 ImmunoVEX HSV2 57 mGluR5 NAM 57 ribavirin therapy 57 estramustine 57 elevated triglyceride levels 57 FTC TDF 57 dapagliflozin plus 57 HPV-#/# 57 anthracycline containing 57 mesalamine granules 57 retrospective cohort 57 C. trachomatis 57 axitinib 57 sCJD 57 receptor blocker 57 TKI therapy 57 IV NSCLC 57 highly emetogenic 57 hepatic resection 57 suppressive therapy 57 Dose escalation 57 NF1 57 achieve sustained virological 57 OAB symptoms 57 allogeneic HSCT 57 Phase IIa trial 57 HCD# [002] 57 JAK2 V#F 57 dasatinib 57 naive HCV genotype 57 null responders 57 HER2 expression 57 Telintra 57 follicular NHL 57 corticosteroid therapy 57 multiple ascending dose 57 NATRECOR ® 57 AVODART 57 randomized multicenter trial 57 INTELENCE 56 familial ALS 56 demonstrated antitumor activity 56 chronic hepatitis B 56 peginterferon alfa 2b 56 invasive candidiasis 56 chronic hepatitis B. 56 mcg BID 56 intra articular injection 56 Epstein Barr virus EBV 56 HCV Genotype 56 Fludara 56 microalbuminuria 56 refractory CTCL 56 renal transplants 56 achieved sustained virologic 56 chronic periodontitis 56 hepatitis B infection 56 paricalcitol 56 genital ulcer disease 56 neurologic progression 56 diagnosed multiple myeloma 56 phase Ib 56 GFT# 56 Immunohistochemical analysis 56 interferon therapy 56 neoadjuvant treatment 56 HER2 overexpression 56 fluvastatin 56 antiretroviral regimen 56 florbetaben 56 antihypertensive therapy 56 idiopathic myelofibrosis 56 ALT flares 56 metastatic CRPC 56 Laquinimod 56 chemoresistant 56 maraviroc 56 Interferon alpha 56 partial remissions 56 COU AA 56 clade B 56 VA# [002] 56 PEG interferon 56 nonmetastatic 56 cIAI 56 docetaxel 56 chronic hepatitis 56 sJIA 56 boosted protease inhibitor 56 herpes zoster shingles 56 pancreatic NET 56 minimally symptomatic 56 lymphoma CTCL 56 oral deforolimus 56 TNF antagonist 56 immunodeficient 56 integrase inhibitor 56 GISTs 56 antimicrobial prophylaxis 56 virus HBV 56 diabetic nephropathy 56 cognitively intact 56 placebo controlled clinical trials 56 SIV infection 56 sorafenib Nexavar 56 microbiologically evaluable 56 randomized #:# 56 efavirenz EFV 56 non metastatic osteosarcoma 56 OHR/AVR# 56 GAMMAGARD 56 gastrointestinal stromal tumors GIST 56 TTR gene 56 Alequel 56 patients undergoing CABG 56 Tamibarotene 56 abiraterone 56 Aspergillus infections 56 temozolomide 56 Juvenile Idiopathic Arthritis 56 radical cystectomy 56 SSc patients 56 randomized 56 mapatumumab 56 teriparatide 56 idarubicin 56 cell lymphoma CTCL 56 ORMD 56 dacarbazine 56 nucleoside naive patients 56 JVRS 56 cancer mCRC 56 Phase III HEAT 56 HCV antibody 56 inecalcitol 56 anti TNF alpha 56 untreated metastatic melanoma 56 therapeutic regimens 56 multidrug resistant 56 lopinavir 56 enterococcal 56 Genz # 56 serum lipid levels 56 antibody titer 56 squamous cell lung cancer 56 imipenem 56 IMC A# 56 sCD# 56 IFN alfa 56 SSc 56 atypical Hemolytic Uremic Syndrome 56 K#R [002] 56 EoE 56 BRCA mutation 56 HRPC 56 standard chemotherapy regimen 56 severe neutropenia 56 previously untreated follicular 56 daily subcutaneous injections 56 amisulpride 56 UPLYSO 56 recurrent VTE 56 TACI mutations 56 MYDICAR ® 56 glycated hemoglobin levels 56 dose escalation trial 56 alanine aminotransferase ALT 56 smoldering multiple myeloma 56 PEG IFN 56 SJIA 56 breast carcinoma 56 Severe Sepsis 56 XELOX 56 Phase IIB 56 anti EGFR antibody 56 hepatitis C infection 56 leukemic stem cells 56 BRCA mutation carriers 56 KRAS mutant tumors 56 tenofovir emtricitabine 56 biologic DMARD 56 GRNOPC1 cells 56 Degarelix 56 DMARD 56 CD8 T cell 56 K RAS 56 talabostat 56 LY# [003] 56 bortezomib 56 opioid dependent 56 FLT3 56 relapsed Hodgkin lymphoma 56 TBC# 56 chronic hepatitis cirrhosis 56 AAV2 56 metastatic HRPC 56 ARV therapy 56 radiotherapy RT 56 elvitegravir 56 Aplidin 56 Vectibix monotherapy 56 immune reconstitution 56 ribavirin 56 interferon IFN 56 neoadjuvant 56 neutralizing antibody 56 single ascending dose 56 denufosol 56 stavudine d4T 56 PBMCs 56 locoregional disease 56 ertapenem 56 AGHD 56 Diamyd ® 56 polycythemia vera essential thrombocythemia 56 Quinamed 56 cilengitide 56 FOLFIRI 56 calcineurin inhibitor 56 seroprotection 56 NO# [002] 56 macroalbuminuria 56 CsA 56 CD4 + 56 Arranon 56 BRCA1 mutation carriers 56 heterozygous FH 56 VZV 56 baseline HbA1c 56 hemodialysis patients 56 Phase IIA 56 interferon beta 1a 56 relapsed leukemia 56 FOLFIRINOX 56 placebo controlled 56 bosentan 56 alefacept 56 refractory prostate cancer 56 Allovectin 7 ® 56 OADs 56 GvHD 56 SIV infected 56 HbA1c levels 56 golimumab CNTO 56 interferon 56 weekly intravenous infusions 56 refractory acute myeloid 56 HLA DR4 56 Phase 1a clinical 56 diagnosed GBM 56 primary hypercholesterolemia 56 SUTENT 56 progressive PsA 56 median CD4 56 gemcitabine carboplatin 56 protease inhibitors PIs 56 elevated ALT 56 carboplatin paclitaxel 56 immunosuppressed 56 docetaxel Taxotere ® 56 oral antidiabetic medication 56 myeloproliferative neoplasms 56 tyrosine kinase inhibitors 56 nutlin 3a 56 Severe Primary IGFD 56 bacteraemia 56 TYSABRI therapy 56 stable angina 56 Phase #/#a trial 56 serum HBV DNA 56 LRAT 56 antiviral efficacy 56 indinavir 56 refractory gout 56 Sapacitabine 56 antifungal therapy 56 Rheumatoid Arthritis RA 56 antiretroviral regimens 56 lumiliximab 56 acute STEMI 56 Altastaph 56 targeting CD# 56 sero positive 56 standard chemotherapy regimens 56 pegylated liposomal doxorubicin PLD 56 HuMax CD4 56 metastatic gastric 56 zoledronic acid 56 antibody responses 56 HDACi 56 daunorubicin 56 EDSS scores 56 hepatectomy 56 onset atrial fibrillation 56 adjuvant radiotherapy 56 Telbivudine 56 telomere lengths 56 atypical hemolytic uremic syndrome 56 undetectable hepatitis C 56 ALND 56 ABSORB trial